MOH withdraws Antipyretic and Pain Reliever Panadol Baby And Infant
The Ministry of Health announced Wednesday that it withdrew the antipyretic and pain reliever Panadol Baby and Infant upon a request from GlaxoSmithKline, the producer of the drug. A mistake was discovered in the dosage rates written on the package of the product, which could lead to liver problems, head of the Ministry’s drug registration Department Rami Behbehani said in press statements.
He asked all physicians not to prescribe Panadol Baby and Infant for the time being until GlaxoSmithKline finalizes the revision of the dosage info. Bebehani also advised parents to stop giving their kids this drug and turn to alternatives that their doctors might recommend.
"It is hard to fail, but it is worse never to have tried to succeed."